450P Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620643
Title:
450P Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life.
Authors:
Lamarca, Angela; McCallum, Lynne; Nuttall, Christina; Barriuso, Jorge; Frizziero, Melissa; Leon, Rebecca; Mansoor, Was; McNamara, Mairéad G ( 0000-0002-2272-3678 ) ; Hubner, Richard A ( 0000-0002-7081-8823 ) ; Valle, Juan W ( 0000-0002-1999-0863 )
Affiliation:
Medical Oncology, The Christie NHS Foundation Trust, Manchester
Citation:
450P Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life. 2017, 28(suppl_5): Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620643
DOI:
10.1093/annonc/mdx368.022
Additional Links:
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx368.022/4108671/450PPancreatic-exocrine-insufficiency-PEI-in
Type:
Meetings and Proceedings
Language:
en
ISSN:
0923-7534; 1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLamarca, Angelaen
dc.contributor.authorMcCallum, Lynneen
dc.contributor.authorNuttall, Christinaen
dc.contributor.authorBarriuso, Jorgeen
dc.contributor.authorFrizziero, Melissaen
dc.contributor.authorLeon, Rebeccaen
dc.contributor.authorMansoor, Wasen
dc.contributor.authorMcNamara, Mairéad Gen
dc.contributor.authorHubner, Richard Aen
dc.contributor.authorValle, Juan Wen
dc.date.accessioned2017-11-21T21:41:04Z-
dc.date.available2017-11-21T21:41:04Z-
dc.date.issued2017-09-
dc.identifier.citation450P Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.issn1569-8041-
dc.identifier.doi10.1093/annonc/mdx368.022-
dc.identifier.urihttp://hdl.handle.net/10541/620643-
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx368.022/4108671/450PPancreatic-exocrine-insufficiency-PEI-inen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title450P Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.